Islet Scis., Inc. v. Brighthaven Ventures, LLC

2017 NCBC 4
North Carolina Business Court·Decided January 12, 2017·No. 15-CVS-16388·Published

Opinion

Islet Scis., Inc. v. Brighthaven Ventures, LLC, 2017 NCBC 4.

STATE OF NORTH CAROLINA IN THE GENERAL COURT OF JUSTICE SUPERIOR COURT DIVISION COUNTY OF WAKE 15 CVS 16388

ISLET SCIENCES, INC. ) Plaintiff, ) ) v. ) OPINION AND ORDER ON ) GREEN AND WILKISON’S ) MOTIONS BRIGHTHAVEN VENTURES, LLC, ) JAMES GREEN, WILLIAM WILKISON, ) OFSINK LLC, and DARREN OFSINK, ) Defendants, ) ) and ) ) BRIGHTHAVEN VENTURES LLC, ) Third-Party Plaintiff, ) ) v. ) ) JOHN F. STEEL, IV, EDWARD T. ) GIBSTEIN, and COVA CAPITAL ) PARTNERS, LLC, ) Third-Party Defendants. )

THIS MATTER comes before the Court on Defendants James Green and

William Wilkison’s Motion for Judgment on the Pleadings (“Motion for Judgment”)

pursuant to Rule 12(c) of the North Carolina Rules of Civil Procedure (“Rule(s)”) and

their Motion to Dismiss First Amended Complaint (“Motion to Dismiss Amended

Complaint”) pursuant to Rule 12(b)(6) (collectively “Motions”).

THE COURT, having considered the Motions, the briefs in support of and in

opposition to the Motions, the oral arguments of counsel presented at the hearing,

and other appropriate matters of record, concludes that the Motion for Judgment should be GRANTED, in part, and DENIED, in part, and the Motion to Dismiss

Amended Complaint should be GRANTED, in part, and DENIED, in part, for the

reasons set forth below.

McGuireWoods LLP by Michael F. Easley, Jr, Esq., Irving M. Brenner, Esq., Michael L Simes, Esq., for Plaintiff Islet Sciences, Inc and for Third-Party Defendants John F. Steel, IV, Edward T. Gibstein, and COVA Capital Partners, LLC.

Parry Tyndall White by K. Allan Parry, Esq., for Defendants James Green and William Wilkison.

Jerry Meek, PLLC by Gerald F. Meek, Esq. for Defendant Brighthaven Ventures, LLC.

Young Moore and Henderson, P.A. by Walter E. Brock, Jr., Esq. for Defendants Offsink LLC and Darren Offsink.

McGuire, Judge.

FACTUAL AND PROCEDURAL BACKGROUND

1. The Court does not make findings of fact on a motion for judgment on

the pleadings; rather, “[a]ll allegations in the nonmovant’s pleadings, except

conclusions of law, legally impossible facts, and matters not admissible in evidence

at trial, are deemed admitted by the movant for the purposes of the motion.” Ragsdale

v. Kennedy, 286 N.C. 130, 137, 209 S.E.2d 494, 499 (1974).

2. Plaintiff Islet Sciences, Inc. (“Islet” or “Plaintiff”) is a public corporation

organized and existing under the laws of the State of Nevada with its headquarters

in Raleigh, North Carolina. Islet is in the business of developing and commercializing

new medicines and technologies to treat patients suffering from metabolic disease. 3. Defendant Brighthaven Ventures, LLC (“BHV”) is a privately-owned

pharmaceutical research and development company headquartered in Raleigh, North

Carolina. BHV develops pharmaceutical products to treat obesity-related health

complications. Defendants James Green (“Green”) and William Wilkison (“Wilkison”)

own BHV.

4. At all times relevant to this lawsuit, BHV was developing the SGLT2

inhibitor remoglifozin etzbonate (“Remo”) to treat type 2 diabetes and nonalcoholic

steatohepatitis. At the time the complaint was filed, Remo was in phase IIb clinical

development. In or about 2010, BHV entered into a licensing agreement with Kissei

Pharmaceuticals (“Kissei”), the original creator and developer of Remo, for exclusive

worldwide rights to Remo excluding the territory of Japan (“Kissei License”). The

Kissei License required BHV to pay “‘milestone’ payments based on the progress of

Remo through the various clinical stages,” equaling approximately $67,500,000. (Am.

Compl. ¶ 14.)

5. On or around September 2013, Islet, through its investment banker

COVA Capital Partners (“COVA”) and its principal and CEO Edward Gibstein

(“Gibstein”), approached Green and Wilkison about joining Islet’s management team

and about Islet and BHV jointly developing Remo. On October 25, 2013, Islet’s board

appointed Green as CEO and Wilkison as COO of Islet. On October 30, 2013, Islet

executed written Employment Agreements with Green and Wilkison (“Employment

Agreements”). 6. Islet and BHV thereafter negotiated the terms of a license for Remo from

BHV to Islet. Plaintiff alleges that “[b]ecause Green and Wilkison were both officers

of Islet and joint owners of BHV, they were negotiating on both sides of the

transaction” and “committ[ed] Islet to terms that were favorable to the defendants

and directly against Islet’s interests.” (Id. ¶ 19.)

7. On January 25, 2014, COVA suggested to Islet’s board of directors that

Islet acquire BHV instead of licensing Remo from BHV. Subsequently, the parties

discussed Islet’s acquisition of BHV in exchange for an “upfront minority share grant

plus additional milestone payments related to Remo’s development” to be paid to

Green and Wilkison. (Id. ¶ 22.) During the same period, Green negotiated a reduction

of the amount of the milestone payments to be made by BHV to Kissei from

$67,500,000 to $25,000,000. (Id. ¶¶ 23–25.) Plaintiff alleges that the more than $40

million in payment reductions should have inured to the benefit of Islet, but Green

and Wilkison subsequently engaged in “self-dealing” to “steal the benefit” of reduced

milestone payments for the benefit of Green, Wilkison, and BHV. (Id. ¶ 26.)

8. On or about February 9, 2014, the parties agreed on the “key terms” of

a merger pursuant to which Islet was to acquire a 100% membership interest in BHV

“in exchange for Islet issuing 30 million shares of Islet common stock to Green and

Wilkison and the potential for up to $71 million of additional purchase price

payments based on the achievement of certain milestones.” (Id. ¶ 27.) Plaintiff alleges

that the decision as to whether the milestone payments would be made in cash or in shares of Islet stock was to be made exclusively by the Islet board of directors. (Id. ¶

31.)

9. Islet was in need of capital, so on or about February 11, 2014, Green and

Wilkison, along with Gibstein, met with Richard Schoninger (“Schoninger”) to solicit

investments from Schoninger and others. Schoninger agreed to invest $1 million in

Islet in exchange for Green’s and Wilkison’s agreement to sell BHV to Islet on the

terms described above. In exchange for his $1 million, Schoninger received 4 million

common shares of Islet common stock. Plaintiff alleges that “Green and Wilkison

diverted some or all of [Schoninger’s investment] to the benefit of [ ] BHV in violation

of their fiduciary duties to Islet and its shareholders.” (Id. ¶ 34.)

10. On March 7, 2014 Islet’s board was presented with a letter of intent to

merge with BHV that contained terms that were “materially different” from the terms

that Green and Wilkison had agreed to with Schoninger and COVA, and more

favorable to Green and Wilkison. For example, the letter of intent removed Islet’s

discretion to make milestone payments to Green and Wilkison in cash and required

Islet to make the payments in shares of Islet stock. The letter of intent also changed

the method of valuing the stock to one much more favorable to Green and Wilkison.

Plaintiff alleges that “Green and Wilkison . . . made the changes to the merger

structure in order to benefit themselves at the expense of Islet and its [ ]

shareholders.” (Id. ¶ 37.) Plaintiff also alleges that Green and Wilkison delayed the

Free access — add to your briefcase to read the full text and ask questions with AI

Islet Scis., Inc. v. Brighthaven Ventures, LLC, 2017 NCBC 4 (N.C. Super. Ct. 2017).

2017 NCBC 4 (Islet Scis., Inc. v. Brighthaven Ventures, LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Atherton v. Federal Deposit Insurance Corp.
519 U.S. 213 (Supreme Court, 1997)
Jackson v. Bumgardner
347 S.E.2d 743 (Supreme Court of North Carolina, 1986)
Ragsdale v. Kennedy
209 S.E.2d 494 (Supreme Court of North Carolina, 1974)
Davis v. Durham Mental Health/Development Disabilities/Substance Abuse Area Authority
598 S.E.2d 237 (Court of Appeals of North Carolina, 2004)
Sutton v. Duke
176 S.E.2d 161 (Supreme Court of North Carolina, 1970)
Watts v. Cumberland County Hospital System, Inc.
343 S.E.2d 879 (Supreme Court of North Carolina, 1986)
Ford v. Peaches Entertainment Corp.
349 S.E.2d 82 (Court of Appeals of North Carolina, 1986)
Benton v. W. H. Weaver Construction Co.
220 S.E.2d 417 (Court of Appeals of North Carolina, 1975)
Cline v. Cline
255 S.E.2d 399 (Supreme Court of North Carolina, 1979)
Bowen v. Darden
84 S.E.2d 289 (Supreme Court of North Carolina, 1954)
Wendell v. Long
418 S.E.2d 825 (Court of Appeals of North Carolina, 1992)
Reese v. Charlotte-Mecklenburg Board of Education
676 S.E.2d 481 (Court of Appeals of North Carolina, 2009)
White v. Consolidated Planning, Inc.
603 S.E.2d 147 (Court of Appeals of North Carolina, 2004)
Schlieper v. Johnson
672 S.E.2d 548 (Court of Appeals of North Carolina, 2009)
Bluebird Corp. v. Aubin
657 S.E.2d 55 (Court of Appeals of North Carolina, 2008)
Leatherman v. Leatherman
256 S.E.2d 793 (Supreme Court of North Carolina, 1979)
Envirokare Tech, Inc. v. Pappas
420 F. Supp. 2d 291 (S.D. New York, 2006)
Teachey v. . Gurley
199 S.E. 83 (Supreme Court of North Carolina, 1938)
Radcliffe v. Avenel Homeowners Ass'n, Inc.
789 S.E.2d 893 (Court of Appeals of North Carolina, 2016)
Perry v. Jordan
900 P.2d 335 (Nevada Supreme Court, 1995)